I think the recent run is due to a combination of factors, such as the whole biotech rebound due to Trump, the Patrick Cox article, and most importantly, the conference call.

I like how the Q&A section focused on partnership questions. That should bring back more investors as we approach some critical milestones next year.

"I wish to point out that Dr. Bertolino is now introducing Prurisol to large pharmas, most of which are embracing it for the first time. We believe that the path to a large financial deal is generation of comparably encouraging data in Phase 2b as recently seen in our completed Phase 2a trial."

http://cellceutix.com/vitae-acquisition-cellc...yCUjH.dpuf

Dr. B's hiring might turn out to be the best acquisition since PolyHeist.